Siegfried Holding AG 2024 AR2
The report highlights Siegfried's continued profitable growth in 2024, with net sales reaching CHF 1,294.6 million and Core EBITDA increasing to CHF 285.6 million. The company advanced its sustainability efforts by submitting science-based greenhouse gas reduction targets to the Science Based Targets initiative (SBTi) for validation. Siegfried achieved an absolute carbon emissions reduction of 45.7% since 2020 and sourced 87% of its electricity from renewable sources. Additionally, the company completed the acquisition of an early-phase CDMO in Grafton, Wisconsin, and opened a new global R&D Center for Drug Substances in Evionnaz.
Company: Siegfried Holding AG
Sector: Health Care
Country: Switzerland
Year: 2024
Type: AR2
Pages: 190
Siegfried Holding AG
Progress Report
The report highlights Siegfried's continued profitable growth in 2024, with net sales reaching CHF 1,294.6 million and Core EBITDA increasing to CHF 285.6 million. The company advanced its sustainability efforts by submitting science-based greenhouse gas reduction targets to the Science Based Targets initiative (SBTi) for validation. Siegfried achieved an absolute carbon emissions reduction of 45.7% since 2020 and sourced 87% of its electricity from renewable sources. Additionally, the company completed the acquisition of an early-phase CDMO in Grafton, Wisconsin, and opened a new global R&D Center for Drug Substances in Evionnaz.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees